Quantessence Capital LLC Invests $971,000 in Illumina, Inc. (NASDAQ:ILMN)

Quantessence Capital LLC acquired a new stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 7,269 shares of the life sciences company's stock, valued at approximately $971,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Golden State Wealth Management LLC bought a new position in Illumina in the 4th quarter valued at about $32,000. Versant Capital Management Inc lifted its holdings in shares of Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock valued at $32,000 after purchasing an additional 146 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich purchased a new position in shares of Illumina during the fourth quarter valued at approximately $45,000. Assetmark Inc. grew its holdings in Illumina by 954.8% during the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock worth $44,000 after buying an additional 296 shares in the last quarter. Finally, Lee Danner & Bass Inc. purchased a new stake in Illumina in the 4th quarter valued at $48,000. Institutional investors own 89.42% of the company's stock.

Wall Street Analysts Forecast Growth

ILMN has been the subject of several recent analyst reports. Guggenheim reduced their target price on shares of Illumina from $170.00 to $150.00 and set a "buy" rating for the company in a research note on Friday, February 7th. Canaccord Genuity Group reduced their price objective on shares of Illumina from $135.00 to $115.00 and set a "hold" rating for the company in a research report on Tuesday, March 11th. Morgan Stanley dropped their target price on shares of Illumina from $150.00 to $136.00 and set an "equal weight" rating on the stock in a research report on Tuesday, February 11th. Stephens reaffirmed an "overweight" rating and issued a $156.00 target price on shares of Illumina in a report on Tuesday, March 11th. Finally, HSBC lowered Illumina from a "buy" rating to a "hold" rating and set a $100.00 price target on the stock. in a report on Friday, February 28th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Illumina presently has a consensus rating of "Moderate Buy" and an average target price of $138.70.

Illumina Stock Performance

Shares of NASDAQ:ILMN traded down $0.26 during trading on Friday, hitting $77.35. 1,424,483 shares of the company were exchanged, compared to its average volume of 2,280,770. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $156.66. The stock has a 50 day moving average of $82.02 and a 200 day moving average of $118.20. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. The company has a market cap of $12.24 billion, a PE ratio of -10.07, a P/E/G ratio of 1.60 and a beta of 1.38.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, equities research analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.